Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium

• Published in: Alimentary pharmacology & therapeutics Vol. 59; no. 10; pp. 1236 - 1247
• Main Authors: Ricciuto, Amanda, Liu, Kuan, El‐Matary, Wael, Amin, Mansi, Amir, Achiya Z., Aumar, Madeleine, Auth, Marcus, Di Guglielmo, Matthew D., Druve Tavares Fagundes, Eleonora, Rodrigues Ferreira, Alexandre, Furuya, Katryn N., Gupta, Nitika, Guthery, Stephen, Horslen, Simon P., Jensen, Kyle, Kamath, Binita M., Kerkar, Nanda, Koot, B. G. P., Laborda, Trevor J., Lee, Christine K., Loomes, Kathleen M., Mack, Cara, Martinez, Mercedes, Montano‐Loza, Aldo, Ovchinsky, Nadia, Papadopoulou, Alexandra, Perito, Emily R., Sathya, Pushpa, Schwarz, Kathleen B., Shah, Uzma, Shteyer, Eyal, Soufi, Nisreen, Stevens, James Patrick, Taylor, Amy, Tessier, M. Elizabeth, Valentino, Pamela, Woynarowski, Marek, Deneau, Mark
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.05.2024; Wiley
• Series: Alimentary Pharmacology and Therapeutics
• Subjects: Cholangitis; Consortia; Endoscopy; Hemoglobin; Inflammatory bowel disease; Inflammatory bowel diseases; Intestine; Life Sciences; Pediatrics; Remission; Remission (Medicine); Sensitivity analysis; Vancomycin

Summary Background Data on oral vancomycin for primary sclerosing cholangitis (PSC)‐associated inflammatory bowel disease (IBD) are limited. Aims Using data from the Paediatric PSC Consortium, to examine the effect of vancomycin on IBD activity. Methods In this retrospective multi‐centre cohort stud...